Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Share information
Events & Presentations
Financial reports
Financial calendar
Shareholder meetings
Shareholder information
Analyst coverage
Corporate governance
ESG
Newsroom
Press Releases
Image library
Glossary
Careers
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
19/03/2024
ASIT Boston – 2024 | A Tolerizing APC-Targeted Vaccibody Vaccine Ameliorates Disease in Mouse Models of Experimental Autoimmune Encephalomyelitis and Non-Obese Diabetes
31/10/2023
SITC – 2023 | Predictive value of circulating tumor DNA in patients with advanced HPV16-positive cervical cancer treated with VB10.16 in combination with atezolizumab
12/10/2023
RNA Cancer Vaccines Summit – 2023 | Antigen presenting cell targeted vaccines
02/10/2023
AACR Special Conference on Tumor Immunology and Immunotherapy – 2023 | High-throughput TCR sequencing demonstrates induction of long-lasting HPV16-specific T-cell responses in VB10.16 vaccinated advanced cervical cancer patients
18/04/2023
AACR – 2023 | Poster ID: CT274 | Individualized APC targeted VB10.NEO cancer vaccines induce broad neoantigen-specific CD8 T cell responses in patients with advanced or metastatic solid tumors: Interim results from a phase 1/2a trial
Pages:
1
2
3
4
5
6
7
8
9
10
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
